



GLOBAL HEPATITIS SUMMIT 2025

LOS ANGELES
USA
MARCH 18 – 21, 2025

Tuesday, March 18, 2025

- 5:00 PM - 6:30 PM
- PLENARY 1 - A Focus On Where We are At
- Opening remarks **John Ward and Norah Terrault**
 - Bridging basic-clinical-implementation spheres in viral hepatitis + Q&A **Jordan Feld**
 - Global progress on hepatitis B, C, and D elimination + Q&A **Meg Doherty**
 - PANEL: Advocacy - coalitions that led to national commitment to elimination

Wednesday, March 19, 2025

- | | | | |
|--------------------|---|---|--|
| 8:30 AM - 10:00 AM | <p>BASIC PARALLEL 1 - HCV virology: replicating success</p> <ul style="list-style-type: none"> • What can we learn from HCV for the other hepatitis viruses? Ralf Bartenschlager • Pharmacology of long-acting HCV therapeutics Andrew Owen • Oral Presentation • Oral Presentation • Oral Presentation • Q&A | <p>CLINICAL PARALLEL 2 - Practical Strategies for implementing Guidelines and Maximizing Treatment Outcomes</p> <ul style="list-style-type: none"> • How to Engage and Support Priority Populations for Viral Hepatitis Care in Non-Endemic Regions Christine Greenway • Development and Expansion of Novel Care Models for a Global Population • Patient and Provider Perspective on Overcoming Barriers to Care Su Wang • Oral Presentation • Oral Presentation • Q&A | <p>CLINICAL PARALLEL 1 - Management of HBV in 2025</p> <ul style="list-style-type: none"> • Interferon as a Component of HBV Cure in 2024 and 2034 Harry Janssen • Invited Talk • Oral Presentation • Oral Presentation • Oral Presentation • Q&A |
|--------------------|---|---|--|

- 10:30 AM - 12:00 PM
- PLENARY 2 - State of the Art: Report Card on Drug Development for HBV: Lessons Learned and the Path Forward
- Report Card on Drug Development for HBV: Lessons Learned and the Path Forward + Q&A **Ed Gane**
 - Oral Presentation + Q&A
 - Oral Presentation + Q&A
 - Introductory Talk
 - Panel - HBV Therapeutics (what's needed now and in the future) + Q&A

- | | | |
|-------------------|--|---|
| 1:30 PM - 3:00 PM | <p>CLINICAL PARALLEL 3 - ILCA-GHS HCC Symposium</p> <ul style="list-style-type: none"> • Risk stratification – HBV and post-SVR • Debate – Are there patients that we can stop surveillance in low risk patients? Neil Mehta • Early detection/screening – surveillance underuse and emerging modalities Ju Dong Yang • Panel – implementation of these strategies Neil Mehta; Ju Dong Yang | <p>BASIC PARALLEL 2 - MishMASH: molecular mechanisms for liver disease</p> <ul style="list-style-type: none"> • MASH: molecular underpinnings of novel therapeutics Percy Knolle • Inflammatory premise for cancer • Oral Presentation • Oral Presentation • Oral Presentation • Q&A |
|-------------------|--|---|

- | | | |
|-------------------|--|--|
| 3:30 PM - 5:00 PM | <p>CLINICAL PARALLEL 5 - Delta Therapies -- Current and Future</p> <ul style="list-style-type: none"> • Overview of New Drug Development for Hepatitis Delta • Bulevirtide (BLV) as Monotherapy or Combination Treatment with Interferon for Hepatitis Delta Maria Buti • Oral Presentation • Oral Presentation • Oral Presentation • Q&A | <p>CLINICAL PARALLEL 4 - Optimizing HBV Treatment: Propsects for a functional cure</p> <ul style="list-style-type: none"> • Progress towards a Sterilizing Cure - Advances in Gene editing and Targeting cccDNA Fabien Zoulim • The Role of RNA interference (siRNA, ASO) as the backbone of HBV Cure strategies Kosh Agarwal • Invited Talk • Oral Presentation • Oral Presentation • Q&A |
|-------------------|--|--|

Thursday, March 20, 2025

8:30 AM - 10:00 AM	<p>BASIC PARALLEL 3 - "Dueling" virology: HBV and HDV</p> <ul style="list-style-type: none"> • Molecular basis for an HBV cure using antivirals Chloe Thio • From controlling HDV to HDV cure Marc Ghany • Oral Presentation • Oral Presentation • Oral Presentation • Q&A 	<p>CLINICAL PARALLEL 6 - HBV Treatment Challenges and Controversies</p> <ul style="list-style-type: none"> • Do Not Stop Long-Term NA Therapy in Absence of Functional Cure (against) Anna Lok • You Can Stop Long-Term Therapy in Absence of Functional Cure (for) • What is the Evidence for Expanding NA Therapy Patrick Kennedy • Oral Presentation • Oral Presentation • Oral Presentation • Q&A
10:30 AM - 12:00 PM	<p>PLENARY 3 - State of the Art: Thinking outside the Box for HCV: Treat to Cure and Eliminate</p> <ul style="list-style-type: none"> • Thinking outside the Box for HCV: Treat to Cure and Eliminate + Q&A Margaret Hellard • Oral Presentation + Q&A • Oral Presentation + Q&A • Introductory Talk • Panel + Q&A 	
1:30 PM - 3:00 PM	<p>BASIC PARALLEL 4 - Exploiting adaptive immunity to combat viral hepatitis</p> <ul style="list-style-type: none"> • Restoring immunity to cure hepatitis B Ulrike Protzer • Immunologic prescription for a vaccine to prevent chronic hepatitis C Andrea Cox • Oral Presentation • Oral Presentation • Oral Presentation • Q&A 	<p>CLINICAL PARALLEL 7 - New Diagnostics and Technologies in Liver Disease - Potential for Current and Future Clinical Practice</p> <ul style="list-style-type: none"> • Novel Biomarkers and Point of Care Tests for HBV management • Application of Artificial Intelligence in Viral Hepatitis • Oral Presentation • Oral Presentation • Oral Presentation • Q&A
3:30 PM - 5:00 PM	<p>CLINICAL PARALLEL 8 - Overlapping Epidemics: Viral Hepatitis Meets Steatotic Liver Disease</p> <ul style="list-style-type: none"> • Alcohol and Viral Hepatitis: How Much is too Much? Jennifer Flemming • Risk of HCC in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Viral Hepatitis • Oral Presentation • Oral Presentation • Oral Presentation • Q&A 	
3:30 PM - 5:30 PM	<p>CLINICAL PARALLEL 9 - Remaining Challenges in Hepatitis C</p> <ul style="list-style-type: none"> • HCV : Improving care after HCV diagnosis and after HCV Cure Jennifer Price • Treatment of HCV in Context of HCC - Remaining Challenges in 2025 • Oral Presentation • Oral Presentation • Oral Presentation • Q&A 	
Friday, March 21, 2025		
8:30 AM - 10:00 AM	<p>CLINICAL PARALLEL 10 - Special Populations in Viral Hepatitis</p> <ul style="list-style-type: none"> • Immunocompromised Patients and Viral Hepatitis Management • Management of Children with Viral Hepatitis (i.e., Immuntolerant or High Replicative, Non-Inflammatory) • Oral Presentation • Oral Presentation • Oral Presentation • Q&A 	<p>BASIC PARALLEL 5 - Gene- and Cell therapies - latest news</p> <ul style="list-style-type: none"> • CAR-T cells in liver transplantation Elmar Jaeckel • Gene correction in the liver using CRISPR Alexander Ploss • Oral Presentation • Oral Presentation • Oral Presentation • Q&A
10:30 AM - 12:00 PM	<p>PLENARY 4 - State of the Art: Towards Achieving Health Equity</p> <ul style="list-style-type: none"> • Australia Greg Dore • UK • Spain Camila Picchio • Africa Ponsianoo Ocama • Brazil Thor Dantas • China • Panel + Q&A 	
Time Zone: (UTC-08:00) Pacific Time (US & Canada) [Change Time Zone]		